** Shares of gene therapy developer Regenxbio RGNX.O rise 23.6% to $8.59 premarket
** RGNX says it has partnered with Japan's Nippon Shinyaku Co 4516.T to develop and commercialize two gene therapies, RGX-121 and RGX-111, to treat Mucopolysaccharidoses (MPS) Diseases
** MPS is a group of inherited metabolic diseases where the body lacks specific enzymes needed to break down complex sugars
** RGNX will receive $110 mln as upfront payment and up to $700 mln as milestone payments from Nippon Shinyaku
** Deal expected to close by the end of Q1 2025
** All 11 brokerages rate the stock "buy" or higher; their median PT is $38 - LSEG
** RGNX fell ~60 in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.